An interventional study of ACT (Adjustable Continence Therapy) in Urinary Incontinence, sponsored by Uromedica. Completed at 7 sites in 2 countries. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-09.
Sponsored by Uromedica · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.
Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 60th largest by enrollment of the 249 interventional ones that give a count, is the only one that started in 2001, is one of 144 with no phase, and was the 10th registered.
986 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.
Browse Urinary Incontinence studies →33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 18+ · Women only
Duke University · Sites in United States
Ages 18+ · Men only
Ohio State University · Sites in United States
Ages 18+ · Women only
The Methodist Hospital Research Institute · Sites in United States
Ages 22–80 · Men only · Healthy volunteers
University of Miami · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 23 · Phase 3 38 · Phase 4 35
First in 1993; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 221 is above the median of 66 across 743 interventional studies indexed under Urinary Incontinence.
Median enrollment 75 across the 249 interventional studies, 100 across the 43 observational. Of the 219 that completed or were terminated, 105 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 293 have an industry lead sponsor. The 10 most frequent:
Uromedica is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Uromedica has 3 studies filed under Urinary Incontinence — fewer than ten, so there is no comparison to draw.
16 of the studies in Urinary Incontinence with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT04565925The University of Texas Medical Branch, GalvestonSildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries | 2026-12-01 |
| NCT07534696University of California, Los AngelesEvaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy | 2026-12-31 |
| NCT06226220University of ChicagoPercutaneous Nerve Evaluation Trial Time | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 293 studies in Urinary Incontinence with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 160 implanted female patients in which two adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress incontinence.
The results will be analyzed to demonstrate the effects of the device as well as its associated risks. Therapeutic success will be based on whether the patients demonstrate at least a one-grade (mean) reduction in the Stamey score at 12 months.
This is a multi-center, prospective, non randomized clinical trial comparing baseline data to the 12 month data. Urodynamic testing, pad weights and a direct visual stress test will be used to determine success along with the Stamey score.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open Label Study, ACT (Adjustable Continence Therapy)
Device: ACT (Adjustable Continence Therapy)
surgically implanted device
Change of Stamey Grade From Baseline to 12 Months.
The Stamey grade classifies the severity of stress incontinence in four possible grades from 0-3. Grade 0: no leaking, Grade 1: loss of urine with sudden increases of abdominal pressure: e.g. coughing, sneezing or laughing, Grade 2: loss of urine with lesser degrees of stress: e.g. walking or standing up, and Grade 3: loss of urine without any relation to physical activity or position, e.g. while lying in bed. The primary end point at 12 months is a mean change in Stamey Grade from baseline of greater than or equal to -1.
Time frame: Baseline to 12 months
Incontinence Quality of Life (IQoL) Questionnaire
Change on Incontinence Quality of Life (IQoL) Questionnaire from baseline to 12 months. 0 being lowest quality of life, 100 being highest quality of life.
Time frame: Baseline to 12 months
Incontinence Impact Questionnaire (IIQ-7)
Incontinence Impact Questionnaire (IIQ-7) change from baseline to 12 months. Scores range from 0-100. 0 being impact from incontinence, 100 being most impacted from incontinence.
Time frame: Baseline to 12 months
Urinary Distress Inventory (UDI-6)
Change on Urinary Distress Inventory (UDI-6) questionnaire from baseline to 12 months. 0 being not distressed, 100 being very distressed.
Time frame: Baseline to 12 months
Number of Incontinence Episodes Per Day (Voiding Diary)
Change in Number of Incontinence Episodes Per Day from baseline to 12 months. 0 being the best.
Time frame: Baseline to 12 months
Number of Pads Changed Per Day (Voiding Diary)
Change in Number of Pads Changed Per Day from baseline to 12 months. 0 pads changed a day being the best.
Time frame: Baseline to 12 months
Provocative Pad Weight
Change in weight of pads (gm) from baseline to 12 months. 0 gm pad weight being the best.
Time frame: Baseline to 12 months
A total of 10 investigational sites in US and 2 in Canada which were clinics,University hospitals or Research centers implanted patients in this study from the period 2001-2006.A total of 221 patients have been enrolled(218 with enrollment data) and 163 of those patients underwent an implant procedure.
| Milestone | ACT Adjustable Continence Therapy for Women |
|---|---|
| Started | 221 |
| Treated | 162 |
| Completed | 142 |
| Not completed | 79 |
| Withdrew: Baseline failure | 59 |
| Withdrew: Permanently explanted | 7 |
| Withdrew: Death | 1 |
| Withdrew: Missed followup | 4 |
| Withdrew: Lost to follow-up | 8 |
The Stamey grade classifies the severity of stress incontinence in four possible grades from 0-3. Grade 0: no leaking, Grade 1: loss of urine with sudden increases of abdominal pressure: e.g. coughing, sneezing or laughing, Grade 2: loss of urine with lesser degrees of stress: e.g. walking or standing up, and Grade 3: loss of urine without any relation to physical activity or position, e.g. while lying in bed. The primary end point at 12 months is a mean change in Stamey Grade from baseline of greater than or equal to -1.
| units on a scale | Experimental |
|---|---|
| Change of Stamey Grade From Baseline to 12 Months. | -1.17 (-1.33 to -1.01) |
Change on Incontinence Quality of Life (IQoL) Questionnaire from baseline to 12 months. 0 being lowest quality of life, 100 being highest quality of life.
| units on a scale | ACT Adjustable Continence Therapy for Women |
|---|---|
| Incontinence Quality of Life (IQoL) Questionnaire | 28.63 ± 29.69 |
Incontinence Impact Questionnaire (IIQ-7) change from baseline to 12 months. Scores range from 0-100. 0 being impact from incontinence, 100 being most impacted from incontinence.
| units on a scale | ACT Adjustable Continence Therapy for Women |
|---|---|
| Incontinence Impact Questionnaire (IIQ-7) | -26.53 ± 33.07 |
Change on Urinary Distress Inventory (UDI-6) questionnaire from baseline to 12 months. 0 being not distressed, 100 being very distressed.
| units on a scale | ACT Adjustable Continence Therapy for Women |
|---|---|
| Urinary Distress Inventory (UDI-6) | -22.66 ± 24.47 |
Change in Number of Incontinence Episodes Per Day from baseline to 12 months. 0 being the best.
| units on a scale | ACT Adjustable Continence Therapy for Women |
|---|---|
| Number of Incontinence Episodes Per Day (Voiding Diary) | -2.76 ± 5.06 |
Change in Number of Pads Changed Per Day from baseline to 12 months. 0 pads changed a day being the best.
| Number of Pads Changed per Day | ACT Adjustable Continence Therapy for Women |
|---|---|
| Number of Pads Changed Per Day (Voiding Diary) | -1.59 ± 3.63 |
Change in weight of pads (gm) from baseline to 12 months. 0 gm pad weight being the best.
| gm | ACT Adjustable Continence Therapy for Women |
|---|---|
| Provocative Pad Weight | -31.03 ± 55.27 |
Collected over Entire Study December 2001 to November 2010 at Study Closure. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ACT Adjustable Continence Therapy for Women | 0/163 (0%) | 2/163 (1.2%) | 155/163 (95.1%) |
| Event | ACT Adjustable Continence Therapy for Women |
|---|---|
| Other (non-pelvic)Cardiac disorders | 2/163 |
| port erosionSurgical and medical procedures | 1/163 |
| Event | ACT Adjustable Continence Therapy for Women |
|---|---|
| Other (non-Pelvic)General disorders | 112/163 |
| Other (Pelvic)General disorders | 75/163 |
| UTIRenal and urinary disorders | 75/163 |
| Pain/DiscomfortGeneral disorders | 51/163 |
| Worsening IncontinenceRenal and urinary disorders | 35/163 |
| Balloon MigrationGeneral disorders | 27/163 |
| Urinary RetentionRenal and urinary disorders | 24/163 |
| Port ErosionGeneral disorders | 21/163 |
| Yeast InfectionRenal and urinary disorders | 21/163 |
| PerforationGeneral disorders | 14/163 |
| Age, Categorical(Participants) | Experimental |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 39 |
| >=65 years | 123 |
| Age, Continuous(years) | Experimental |
|---|---|
| Mean | 67.6 ± 11.6 |
| Sex: Female, Male(Participants) | Experimental |
|---|---|
| Female | 162 |
| Male | 0 |
| Region of Enrollment(participants) | Experimental |
|---|---|
| United States | 137 |
| Canada | 25 |
The record gives a start of Dec 2001, a primary completion of Jul 2008 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2018, 9 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Uromedica